A patient is eligible for treatment with an investigational drug, biological product, or device if the patient has:
- (1) considered all other treatment options currently approved by the United States food and drug administration;
- (2) received a recommendation from the patient's treating health care provider for an investigational drug, biological product, or device;
- (3) given written informed consent for the use of the investigational drug, biological product, or device; and
- (4) documentation from the treating health care provider that the patient meets the requirements of this section.
History: En. Sec. 4, Ch. 135, L. 2015; amd. Sec. 3, Ch. 413, L. 2023.